Erik Haeffler, vice president of manufacturing services, Recipharm, examines the challenges and opportunities for a CDMO in the landscape of serialisation that contract partners must overcome.
With growing concerns surrounding counterfeit medicines and the threat they pose to patient safety, the pharmaceutical industry is introducing varying serialisation mandates across the global market.